Mapping the peritoneal immune system to identify novel immunomodulatory treatment options for diseases with peritoneal involvement.

Mapping the peritoneal immune system to identify novel immunomodulatory treatment options for diseases with peritoneal involvement. - MAPS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52795

Enrollment

180

Registered

2019-08-28

Start date

2020-06-04

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric- and colon cancer (cancer of the stomach and large intestine)

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Both males and females will be included in this study. To minimize the potential risk of age and gender differences in the peritoneal immune system, we will age and gender-match the samples for analyses from the control groups and the peritoneal metastases group. Patients are eligible when aged >18 old.

Exclusion criteria

Exclusion criteria: The following general criteria will lead to exclusion from participation in this study: a. No informed consent is provided by patient or its legal representative b. Signs of bleeding in the peritoneal cavity, as this will lead to contamination of blood immune cells in the peritoneal cavity c. Presence of intra-abdominal medical devices or corpus aliena, as this could elicit a local inflammatory response d. History of active peritoneal dialysis (CAPD) e. Recent history (

Design outcomes

Primary

Measure	Time frame
The goal of this explorative study is to establish a correlation map between the healthy peritoneal immune compartment and the peritoneal immune composition in patients with peritoneal metastasized disease. Clustering of transcriptional (scRNA-Seq) and cell surface protein expression (CyTOF) allows for identification of immune cell populations and our main study parameter will be differences in immune cell populations between peritoneal fluid from patients without peritoneal involvement and peritoneal fluid of patients with peritoneal involvement.	—

Measure

Time frame

The goal of this explorative study is to establish a correlation map between the healthy peritoneal immune compartment and the peritoneal immune composition in patients with peritoneal metastasized disease. Clustering of transcriptional (scRNA-Seq) and cell surface protein expression (CyTOF) allows for identification of immune cell populations and our main study parameter will be differences in immune cell populations between peritoneal fluid from patients without peritoneal involvement and peritoneal fluid of patients with peritoneal involvement.

—

Countries

Netherlands

Contacts

Public ContactJ Grootjans

Amsterdam UMC

j.grootjans@amsterdamumc.nl020 444 4444

Outcome results